

Abingworth Management Ltd

Investor

Mr. Timothy Haines

Partner

www.abingworth.com

Based in: United Kingdom

Ownership: Private

MISSION/BACKGROUND

Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing for more than 90 unquoted life science businesses.

The majority of these have gone public or have merged or been acquired. Abingworth has funds under management of more than \$1.25 billion. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston.

Abingworth's funds are exclusively dedicated to life sciences. Abingworth's team has a strong scientific background in addition to business, financial and other specialist skills. These include legal, investment banking, fund-raising as well as operating and recruiting capabilities. These resources are extended to portfolio companies in order to help build successful companies. Abingworth's team offering is further complemented by a network of scientific and industry consultants who contribute to the process of evaluating new opportunities, creating companies and supporting existing portfolio investments.

This combination of broad-ranging experience and resources enables Abingworth to assist companies at any stage of development, including during and after the IPO process.

Abingworth seeks to invest in the best opportunities in the life sciences market. Investments have been made in platform and enabling technologies, devices and instrumentation as well as in companies developing products in a range of therapeutic areas.

Abingworth's investments are based in the US and Europe including the UK, Belgium, Denmark, France, Germany, Holland and Sweden. Abingworth's investments range from \$1 to \$25 million, averaging around \$15 million per investment after all private rounds of financing.

BBMEDTECH

BB Medtech AG

Investor

Dr. Martin Münchbach
Member of the Management Team
www.bellevue.ch

Based in: Switzerland
Ownership: Public

MISSION/BACKGROUND

BB MEDTECH AG was established as an investment company in Schaffhausen (Switzerland) in November 1995. BB MEDTECH's principal focus is investing in both public and private companies within the global medical technology industry.

Investments in private companies at an earlier stage are taken by BB MEDTECH's sister company BB BIOTECH VENTURES II.



Clinica World Medical Technology News

Medical Technology

Ms. Tina Tan
Medtech Ventures Editor
www.clinica.co.uk

Based in: United Kingdom
Ownership: Private

MISSION/BACKGROUND

Clinica World Medical Technology News is the leading voice of the medical device and diagnostics industry. Offering concise and authoritative coverage of developments that affect your business, Clinica reports on the very latest in global R&D, mergers and acquisitions, product approvals, regulatory updates and market trend analysis.

Through its supplements Medtech Ventures and Medtech Partnering, Clinica brings added value to its readers. Whether you're a start-up developing tomorrow's technology, or a company looking to take its growth to the next level, Medtech Ventures and Partnering provide a platform for potential investment and collaborative opportunities.

CREDIT SUISSE

Credit Suisse

Supplier

Mr. Reto Fehr
Head Financial Planning
www.credit-suisse.com

Based in: Switzerland
Incorporated: 1850
Employees: 45000
Ownership: Public

MISSION/BACKGROUND

In order to achieve our vision, Credit Suisse will set new standards: new standards in partnering with our clients and new standards in providing them with innovative and integrated solutions.

Cultural diversity is essential to the success of Credit Suisse. As an integrated global bank, Credit Suisse will empower people to work openly and respectfully with each other and with clients to deliver superior results that will lead to success and prosperity for all its stakeholders.

PRODUCTS/TECHNOLOGIES/SERVICES

Credit Suisse is a leading global bank headquartered in Zurich. It is focused on serving its clients in three business lines: investment banking, private banking and asset management.

Credit Suisse is renowned for providing expert advice, holistic solutions and innovative products to a wide range of corporate and institutional clients and high-net-worth individuals globally, as well as retail clients in Switzerland.



EBD Group, Inc.

Professional Services and Consulting, Business Development

Dr. Philip Ledger
Senior Consultant
www.ebdgroup.com

Based in: United States
Incorporated: 1993
Employees: 20
Ownership: Private

MISSION/BACKGROUND

EBD Group is the leading partnering firm for the global biotechnology industry.

Since 1993, firms in the life sciences have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business.

EBD Group's conferences (run in collaboration with leading industry partners and international trade associations such as BIO and Eucomed) include BIO-Europe, the world's largest stand-alone life science partnering conference; BIO-Europe Spring; the investor conference BioEquity Europe (co-organized with BioCentury Publications); and the medical technology partnering conference, BioDevice Partnering.

EBD's novel web-based partnering software system is also used at numerous third-party events around the world.

Outside of the conference format, EBD Group's consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in San Diego, Munich and London.

PRODUCTS/TECHNOLOGIES/SERVICES

EBD Group hosts BIO-Europe, BIO-Europe Spring, BioDevice Partnering and BIO-Equity Europe. These annual events bring together pharma, biotechs, medtechs and investors to explore and extend partnerships and collaborations.

EBD Group also offers our acclaimed partnering system to regional and national conferences and exhibitions, with clients in Asia, North America and Europe.

ALLIANCES

EBD hosts international partnering conferences. By offering partnering services to regional and national events, we aim to assist in the growth of the biotech and medtech sectors, whilst helping smaller companies to benefit from the power of best practise partnering facilities. We do not aim to take over or run our client events, so our partnering provision is purely fee for service. The client retains ownership of all data generated.



EPSTEIN BECKER & GREEN P.C.

Epstein Becker & Green, P.C.

Professional Services and Consulting, Legal Services

Mrs. Diane Romza-Kutz

Member of the Firm

www.ebglaw.com

Based in: United States

Incorporated: 1973

Ownership: Private

MISSION/BACKGROUND

The Pharmaceutical and Life Science Industries Practice Group of Epstein Becker & Green, P.C. understands the business, regulatory and scientific issues that confront our Life Science clients worldwide. Our attorneys have the experience and knowledge to effectively service each segment of the Pharmaceutical and Life Science Industries, helping clients with matters ranging from business transactions to litigation, from regulatory approval and compliance to protecting and enhancing the value of their Intellectual Property. We provide clients with the comprehensive legal services they need to help them successfully navigate the challenges of these highly regulated and rapidly evolving global industries.

PRODUCTS/TECHNOLOGIES/SERVICES

The Pharmaceutical and Life Science Industries consist of new and emerging technologies, as well as current technologies that are continuously and rapidly evolving. The federal, state and international laws and regulations that affect these industries change and grow in complexity on a continuous basis. The attorneys at Epstein Becker & Green, P.C. have over 30 years of experience working with these industries, and understand the history, policies and economics shaping these industries today and tomorrow. Our industry clients include: biotechnology companies; dietary supplement developers; manufacturers and distributors working in all segments of the life science industry; information technology companies, food companies, animal feed and veterinary medicine companies; genomics, bioinformatics, proteomics, biologics, combinatorial chemistry, academic medical centers and other research organizations, site management organizations, financial services firms, pharmaceutical developers and manufacturers, medical device manufacturers and distributors, and cosmetic manufacturers and distributors.

We counsel clients on all aspects of product development, including, but not limited to; clinical trials and research, commercialization and the FDA regulatory approval process. We further assist our clients in maximizing the value of their Intellectual Property. We also represent clients in pharmaceutical pricing issues, post market advertising strategies and litigation. We work with clients through every phase of a product's life cycle. This includes the formation and financing of early-stage ventures through the structuring and negotiation of licenses, research collaborations and technology transfer agreements, the protection of human subjects and intellectual property, the securing of regulatory approval, ensuing third party coverage, and the representation of a company in post-approval marketing.





Eidgenössische Technische Hochschule Zürich
Swiss Federal Institute of Technology Zurich

ETH Zürich

Public organization / NPO, University

Dr. Silvio Bonaccio
Head of ETH Transfer
www.transfer.ethz.ch

Based in: Switzerland
Employees: 11
Ownership: Public

MISSION/BACKGROUND

The Swiss Federal Institute of Technology, ETH Zurich is a science and technology university with an outstanding research record. As an internationally oriented institution, ETH Zurich is the study, research and work place of 18,000 people from 80 nations. It hosts about 350 professors in 15 departments teaching and doing research mainly in the engineering sciences and architecture, system-oriented sciences, mathematics and natural sciences areas.

PRODUCTS/TECHNOLOGIES/SERVICES

ETH transfer is the technology transfer office of ETH Zurich. It supports the ETH community in all questions related to cooperation with industry, inventions, patent applications and licensing, as well as setting up ETH spin-off companies. ETH transfer manages the institution's technology portfolio and initiates contacts between external bodies (such as companies and public authorities) and research groups at ETH Zurich. In organisational terms, ETH transfer is attached directly to the Vice Presidency for Research of ETH Zurich.

PRODUCTS/TECHNOLOGIES

<i>Name</i>	<i>Partnering Status</i>
Cotton wool-like biomaterials	Available for out-licensing

ALLIANCES

ETH Zürich has collaborations with industrial partners in almost all scientific and technical areas. The institution has a very flexible approach with regard to interactions with industry and offers its clients and partners a variety of platforms and possibilities to profit from its technologies and expertise.



Eucomed

Public organization / NPO, Industry Association

Dr. Maurice Wagner

Director General

www.eucomed.org

Based in: Belgium

Employees: 15

Ownership: Private

MISSION/BACKGROUND

The mission of Eucomed is to improve patient and clinician access to modern, innovative and reliable medical technology.

PRODUCTS/TECHNOLOGIES/SERVICES

Eucomed members include national trade and pan-European product associations and internationally active manufacturers of all types of medical technology.

FUJIFILM



FUJIFILM Manufacturing Europe BV

Biotechnology related

Mr. Peter Asten
Assistant Manager Life Science
www.fuji-research.com

Based in: Netherlands
Incorporated: 1919
Employees: 70000
Ownership: Public

MISSION/BACKGROUND

Fujifilm will constantly strive to develop superior technologies and to continue to cultivate an imaging and information culture. As a global company fully trusted by both customers and society itself, we aim to make innovative use of the most advanced technologies to create beautiful images and wide-ranging information and provide the imaging, information, and document solutions that will best meet the increasingly sophisticated needs of the world community.

Life Science mission:

FUJIFILM will contribute to 'a society where the people of the world can live in mental & physical health'. By the technology which is cultivated through the creation of 'the culture of Imaging & Information'


PRODUCTS/TECHNOLOGIES/SERVICES

Recombinant gelatins are developed and produced for various medical- and pharmaceutical applications like vaccine stabiliser, tissue engineering, medical device coatings and controlled drug deliveries. Already a portfolio of recombinant gelatins is made but if special features are required, these can be developed tailor-made for the applications.

ALLIANCES

Fujifilm is open for various kinds of collaborations. Depending on the application the collaboration can be based on "selling gelatin to the customer", "co-development of a new recombinant gelatin based product", licensing technologies etc.

Additionally Fujifilm is interested in licensing-in new technologies related to biomaterials and medical devices.



Greater Zurich Area

Expanding business horizons

Greater Zurich Area

Public organization / NPO

Mr. Lukas Huber
Director Life Sciences
www.greaterzuricharea.ch

Based in: Switzerland
Incorporated: 1999
Ownership: Private

MISSION/BACKGROUND

Greater Zurich Area is a leading European centre of medical innovation.

Its Life Science Cluster includes:

- over 400 medical and biotechnology companies
- over 70 university institutes in life sciences
- over 20 clinics at the university hospitals

Offering free location evaluation and regulatory assistance that cover taxes, market environment, work permits, talent availability, real estate, and much more, Greater Zurich Area AG is your ideal partner at all levels of a smooth expansion and relocation of your business. Greater Zurich Area AG is a non-profit economic development agency located in Zurich, Switzerland, and committed to ensuring successful business expansions of foreign companies into the economically and culturally vibrant region in and around Zurich.

With its great expertise in Life Sciences, our professionals will advise you from the inception to the successful launch of your operations in the Greater Zurich Area.

Can we support you?

- Answers to your key questions
- Advice on establishment procedures
- Support to find the right location and people
- Contacts with experts and authorities

MAYER
BROWN
ROWE
& MAW

Mayer, Brown, Rowe & Maw LLP

Professional Services and Consulting, Legal Services

Dr. Rüdiger Herrmann

Partner

www.mayerbrownrowe.com

Based in: Germany

Incorporated: 1891

Employees: 1500

Ownership: Private

MISSION/BACKGROUND

Mayer, Brown, Rowe & Maw LLP is an international law firm with a long and prominent tradition in providing comprehensive legal services to companies from the biotech, pharma, medical device and med-tech, life science, bioinformatics and agribusiness industries. Our representation ranges from some of the largest pharma and medtech corporations in the United States and Europe to start-up biotech, life science and bioinformatics companies. As part of this industry focus, we also represent a significant number of financial investors of these companies, including banks, private equity and venture capital companies, funds, funding organizations and business angels, as well as credit institutions and investment banks throughout Europe, the United States, Canada, Asia and Latin America.

We understand the diverse needs of our many clients in these fields and work closely with each of them regarding all of their legal services' needs, including corporate and financing matters, securing of patents and trademarks, exploitation and commercialization of intellectual property, contract matters, product launches, marketing and competition issues, regulatory, compliance and reimbursement questions, development and implementation of business plans, capital market matters, tax issues as well as the securing of public funding and grants.

This work includes on the contract side, for example, drafting and negotiation of development agreements, clinical trial and research contracts, licenses, university and government arrangements and manufacturing, distribution and supply agreements. On the corporate side, our services cover, for example, company formation, mergers and acquisitions, joint ventures and spin-offs, initial public offerings as well as venture capital, private equity and other financings. Furthermore, we provide advice in any sort of related investment transaction, including, for example, acquisition of shares, silent partnerships, public grants, mezzanine financing, secondary investments and debt transactions.

The pharma, biotech and life science practice of Mayer, Brown, Rowe & Maw LLP is among the leading practices in the world. In November 2006, we have received from one of the most prominent legal publishing and marketing companies in Germany the award as "Pharma and medical device law firm 2006".

In general, Mayer, Brown, Rowe & Maw LLP is among the leading international business law firms. We have more than 1,500 lawyers practicing in six European cities (Berlin, Brussels, Cologne, Frankfurt, London, Paris) and eight cities in the USA and Asia. Furthermore, Mayer, Brown, Rowe & Maw LLP has strategic alliances with law firms in Italy and Spain. For further details, visit our website: www.mayerbrownrowe.com/biotech.

MEDICAL DEVICE DAILY™

THE DAILY MEDICAL TECHNOLOGY NEWSPAPER

AHCMedia / Medical Device Daily

Medical Technology

Mr. John Brosky
European Editor

www.medicaldevicedaily.com

Based in: United States
Ownership: Private

MISSION/BACKGROUND

Medical Device Daily is the newspaper of record for the medical technology industry and is relied on by thousands of industry insiders every business morning. This business-focused intelligence service is the flagship publication of Thomson BioWorld's med-tech group, which also publishes Biomedical Business & Technology, Cardiovascular Device Update, and Diagnostics & Imaging Week. Much like its sister publication BioWorld Today, Medical Device Daily offers unbiased business-focused news to an executive audience trying to stay ahead of the curve in this fast-paced industry.

Launched in 1997 as a weekly faxed publication and converted to a daily in 2001, Medical Device Daily keeps industry insiders alerted to vital information, such as new product developments, company news, regulatory activity, legislative actions, strategic alliances, sales and mergers, market updates, and much more, every business morning. In addition to its daily news reporting online, Medical Device Daily offers an extensive searchable database with articles dating back to its premier issue - perfect for compiling a customized report or searching for specific information on a company, product or person.

PRODUCTS/TECHNOLOGIES/SERVICES

Medical Device Daily

Timely information covering everything affecting the medical device industry.

Relied upon by thousands of industry insiders every business morning, this is the only daily medical technology newspaper. With new product developments, company news, regulatory activity, legislative actions, strategic alliances, sales and mergers, market updates, and much more ? you are alerted to targeted news. That's why this has been a trusted source for the latest developments since 1997.

Biomedical Business & Technology

The numbers and analysis behind the key medical device markets.

Get hard numbers and incisive analysis from the leading source for the high-tech medical device industry. In addition to market size and direction, each monthly issue covers emerging markets, competitors? moves, technology cycles, and more. Plus you can identify and seize opportunities in key medical device markets around the world.

Cardiovascular Device Update

Authoritative coverage on the rapidly growing field of cardiovascular devices.

If you're looking to benefit from emerging opportunities in the rapidly growing field of cardiovascular devices, turn to the only newsletter written specifically for cardiovascular device manufacturers. Every month you get authoritative coverage on emerging technology trends, new products, regulatory updates, company activities, and more!

Diagnostics & Imaging Week

The most recent news and developments in all major areas of diagnostics.

If something is happening in the clinical diagnostics and diagnostic imaging sectors, you'll soon know about it from the pages of this weekly resource. Each issue contains the most recent news and developments in all major areas of diagnostics: microchip technology, cardiovascular disease, point-of-care and self-testing, cancer and genetic testing, and DNA probes.

Medical Technology & Devices Week

Quickly scan news on the biggest medical tech developments.

When you're looking for a reliable and concise report of what's happening in the medical technology and device sectors, this publication is the perfect solution. Formatted for executives who don't have a lot of time, this weekly industry roundup can be scanned in minutes. Pinpoint the news you need and stay up-to-date on the biggest medical technology developments around the world.

Medical Device Daily State of the Industry Report

A variety of perspectives on the med-tech market.

This in-depth annual review of the industry compiles sector and technology outlooks from every facet of the market to provide you with the information you need to make strategic decisions about the direction of the industry. Focused on a comprehensive analysis, this report helps you spot trends and seize opportunities in the med-tech markets. Covers major med-tech market sectors, along with a generous overview of the industry.

nature biotechnology

Nature Publishing Group

Biotechnology

Mr. Graham Combe
Account Development Manager
www.nature.com

Based in: United Kingdom
Ownership: Private

MISSION/BACKGROUND

Scientific and medical excellence in print and online

Nature Publishing Group (NPG) brings leading scientific and medical research to your desk top. The NPG portfolio combines the continued excellence of Nature and its associated research and review journals, over 35 leading academic and society journals and 8 Nature Clinical Practice journals. NPG also provides news content through news@nature.com and scientific career information through Naturejobs.

NPG's Biopharma Industry flagship publications, Nature Biotechnology and Nature Reviews Drug Discovery, each address their field's involvement in the evolving pharmaceuticals landscape, and both continue to be ranked #1 with their groundbreaking editorial content on the science and business of Biotechnology and Drug Discovery. Together these two publications reach 160,000+ thought-leaders mainly from the pharmaceutical and biotech industries, making them your ideal media partner to communicate with this sector.



Organogenesis Inc.

Biotechnology, Regenerative Medicine

Mr. Dario Eklund
Vice President, Biosurgery & Aesthetic Medicine
www.organogenesis.com

Based in: United States
Incorporated: 1985
Employees: 230
Ownership: Private

MISSION/BACKGROUND

Having pioneered the field, Organogenesis is the leading tissue regeneration company. A new era in medicine arrived when Organogenesis received the first FDA approval for a living, human cell-based product. Apligraf® is now the leading tissue regeneration brand in the world. This was the culmination of two decades of cutting edge research by a dedicated team of scientists.

A second distinction is our ability to mass-produce and distribute living technology reliably, timely and conveniently to medical clinics around the world.

A third achievement has been to solidify our position as experts in successfully commercializing living, cell-based brands. We have built a sales and marketing organization dedicated to facilitating the adoption of tissue regeneration brands as a standard-of-care choice for patients. To date, we have treated well in excess of 150,000 patients with Apligraf®. This constitutes over two-thirds of all cell therapies applied to patients worldwide.



Smith & Nephew plc

Medical Technology, Non-active implantable devices, Single use devices, Electro mechanical medical devices, Reusable instruments, Active implantable devices, Biomaterials, Coatings, Regenerative Medicine, Wound Care

Dr. Ceri Batchelder
Senior Technology Analyst
www.smith-nephew.com

Based in: United Kingdom
Incorporated: 1856
Employees: 8800
Ownership: Public

MISSION/BACKGROUND

Smith & Nephew is a medical technology business specialising in Orthopaedic Reconstruction, Orthopaedic Trauma, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has more than 8,800 employees and operates in 33 countries around the world, generating annual sales of nearly \$2.8 billion.

PRODUCTS/TECHNOLOGIES/SERVICES

Products in our two Orthopaedics Businesses include leading-edge joint replacement systems for knees, hips and shoulders, trauma products to help repair broken bones, and a range of other medical devices to help alleviate pain in joints and promote healing.

Our Endoscopy Business offers a broad range of techniques and instruments for minimally invasive surgery, allowing surgeons to access, visualise, resect and repair damaged tissue more efficiently and effectively. The focus is on arthroscopic treatment of the knee, hip and shoulder.

Our Advanced Wound Management Business produces and markets products for managing difficult-to-heal wounds, speeding up the healing process and improving patient quality of life. These products include advanced polymeric gels, films and foams that create a moist environment that encourages healing; and antimicrobial dressings and ointments.

Our Research Centre in York is focussed on biomaterials, cell-based therapies and tissue regeneration for the therapeutic areas of orthopaedics and endoscopy (mainly arthroscopy).

ALLIANCES

We are actively seeking partnerships/collaborations that are applicable to our areas of business. Several representatives will be present from the corporate Research Centre which considers relatively early stage technologies.

SWISS+ MEDTECH

SwissMedtech

Medical Technology

Mr. Lukas Huber
Vice President
www.swiss-medtech.org

Based in: Switzerland
Ownership: Private

MISSION/BACKGROUND

Swiss Medtech unites the four leading medtech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The Swiss MedTech industry of today is a broad entity, consisting of roughly then segments: biomaterials, cardiovascular implants and devices, dental implants and devices, diabetes devices, electro medical and imaging equipment, orthopedics, respiratory equipments, surgical instruments and wound & care management.

Switzerland has positioned itself successfully in this seminal technology sector: Approximately 40,000 employees are working in more than 500 Swiss MedTech firms, a majority of which are small and mid-sized companies.

Their combined annual sales is an estimated CHF 9 billion showing a growth rate of 7% p.a.

Thanks to a serious commitment to <<Swiss Made>> quality levels as a competitive advantage, Switzerland is among the leading countries in the global MedTech sector.

Swiss Medtechs' mission is to spread the message of Switzerland as one of the top medtech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of medical technology including research, education, economics, finance and industry. The bases for success in medical technology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth.

an SWX Group company



SWX Swiss Exchange

Public organization / NPO

Dr. Yvonne Gunsch-Wegmann
Head of Issuer & Investor Relations
www.swx.com

Based in: Switzerland
Ownership: Private

MISSION/BACKGROUND

Swiss financial institutions manage more than one-quarter of the world's offshore assets and represent the backbone of Switzerland's strong financial marketplace. As a result, companies listed on the SWX Swiss Exchange achieve a high level of visibility within this financially potent investor community.

In Switzerland, the life sciences industry in particular has developed into an internationally recognised and strongly emphasized sectoral focal point:

- In Europe, the SWX has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies.
- Collectively, these representatives of the industry account for roughly one-third of the overall market capitalisation.
- Listed companies in the life sciences field such as Novartis, Roche, Merck Serono and Actelion engender an environment that exudes global charisma.
- Differentiated sector-specific indicators such as the SXI LIFE SCIENCES® and SXI Bio+Medtech® indices, as well as the unusually broad analyst coverage of this particular sector, ensure transparency and outstanding visibility.



Windhover Information Inc.

Professional Services and Consulting

Mr. David Cassak

Managing Partner

www.windhover.com

Based in: United States

Ownership: Private

MISSION/BACKGROUND

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, medical device and diagnostic industries. Windhover publications, business conferences, in-depth market reports and databases all help senior executives worldwide in their decision making processes. Based in Norwalk, Conn., the privately held company also has offices in London and Newport Beach, Calif.

PRODUCTS/TECHNOLOGIES/SERVICES

IN VIVO:

The Business & Medicine Report is a monthly publication focused on health care's most significant trends and challenges. Topical, timely and well-written, IN VIVO delivers real insight into the company strategies, technologies and deals reshaping the health care landscape.

START-UP:

Windhover's Review of Emerging Medical Ventures. No publication reviews cutting-edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas and reviews funds flowing into private companies and investment trends.

PHARMACEUTICAL STRATEGIC ALLIANCES:

The industry's most comprehensive guide to drug and biotech alliance activity.

STRATEGIC INTELLIGENCE SYSTEMS:

A proprietary suite of databases provides comprehensive deal activity in the pharmaceutical, medical device and diagnostics industries along with top-level commentary and analysis of these transactions. Strategic intelligence Systems is a powerful research tool used by senior executives and researchers alike to benchmark valuations, structure deals and ensure the highest return on their investments.



Sponsors